Sign up to save your podcasts
Or
Share Lorundrostat: Results from Advance-HTN Phase 2 Study
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lorundrostat: Results from Advance-HTN Phase 2 Study
Luke Laffin, MD, shares the findings from a late breaker he presented at ACC 2025. Lorundrostat is an investigational drug found to significantly lower 24-hour blood pressure among patients with uncontrolled and resistant hypertension.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.
View all episodes
By Cleveland Clinic Heart & Vascular Institute
4.2
4141 ratings
Luke Laffin, MD, shares the findings from a late breaker he presented at ACC 2025. Lorundrostat is an investigational drug found to significantly lower 24-hour blood pressure among patients with uncontrolled and resistant hypertension.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.
More shows like Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals
View all
JAMA Editors' Summary
135 Listeners
AFP: American Family Physician Podcast
696 Listeners
JAMA Clinical Reviews
493 Listeners
JACC This Week
170 Listeners
This Week in Cardiology
887 Listeners
Mayo Clinic Talks
290 Listeners
The Curbsiders Internal Medicine Podcast
3,334 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
139 Listeners
Core IM | Internal Medicine Podcast
1,152 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
86 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Run the List
248 Listeners
Cardionerds: A Cardiology Podcast
430 Listeners
The Curious Clinicians
369 Listeners